Therapeutic Diets for Alzheimer's Disease
(TDAD Trial)
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you must not have had any medication changes within the past 30 days to be eligible.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must not have had any medication changes in the past 30 days before joining.
What data supports the idea that Therapeutic Diets for Alzheimer's Disease is an effective treatment?
The available research shows that therapeutic diets like the ketogenic diet can improve cognitive abilities and quality of life for Alzheimer's patients. Studies have found that once the body enters a state called ketosis, where it uses fat instead of sugar for energy, patients with mild to severe Alzheimer's experience cognitive improvements. These diets have also been linked to better brain metabolism and reduced harmful brain deposits associated with Alzheimer's. Compared to other treatments, ketogenic diets show promise in improving brain function and reducing symptoms.12345
What data supports the effectiveness of the treatment Ketogenic Diet for Alzheimer's Disease?
Research suggests that a ketogenic diet, which is high in fats and low in carbohydrates, may help improve cognitive function and quality of life in people with Alzheimer's disease. Studies have shown that when the brain uses ketone bodies (produced during ketosis) instead of glucose, there can be improvements in memory and a reduction in symptoms associated with Alzheimer's.12345
What safety data exists for therapeutic diets in Alzheimer's treatment?
The safety data for therapeutic diets, particularly ketogenic diets, in Alzheimer's treatment includes evidence from various studies. Adverse effects and compliance strategies are discussed in the literature, with some studies reporting adverse events such as dyslipidemia, constipation, and fatigue. However, these diets have shown potential benefits in cognitive improvement and symptom management in Alzheimer's patients.13678
Is the ketogenic diet safe for humans?
Is the Ketogenic Diet a promising treatment for Alzheimer's Disease?
How does the ketogenic diet treatment for Alzheimer's differ from other treatments?
The ketogenic diet is unique for Alzheimer's treatment because it provides an alternative energy source for the brain through ketone bodies, which can be beneficial when glucose metabolism is impaired, as seen in Alzheimer's. This diet has shown potential in improving cognitive function and reducing neuroinflammation, which are not typically addressed by standard treatments.347910
What is the purpose of this trial?
By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.
Eligibility Criteria
This trial is for individuals aged 50 to 90 with Alzheimer's Disease, as diagnosed by McKhann et al. criteria. Participants must speak English, have a stable medication regimen for the past month, and score 0.5 or 1 on the CDR scale. They need a study partner and cannot be in nursing care or another trial, nor can they have renal stones, insulin-requiring diabetes, recent cancer treatments or cardiac events.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Ketogenic Diet Treatment
Participants adhere to a 1:1 ketogenic diet with supplements for 3 months
Washout Period
Participants halt adherence to the ketogenic diet and resume their normal diet
Therapeutic Lifestyles Changes Diet
Participants adhere to the Therapeutic Lifestyles Changes diet
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Ketogenic Diet
- Therapeutic Lifestyles Changes Diet
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kansas Medical Center
Lead Sponsor
National Institute on Aging (NIA)
Collaborator